BLUE bluebird bio, Inc.: institutional ownership and insider trading
2 funds reported holding $106K of bluebird bio, Inc. in their latest 13F filings; in Q3 2025 funds net bought $0, with 0 new positions and 3 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $104M and net income of −$200M.
BLUE revenue and earnings
- Quarter ended Mar 31, 2025: revenue $38.7M, net income −$29.1M, EPS -2.98
- Quarter ended Dec 31, 2024: revenue $38.5M, net income −$28.7M, EPS -16.88
- Quarter ended Sep 30, 2024: revenue $10.6M, net income −$60.8M, EPS -0.31
- Quarter ended Jun 30, 2024: revenue $16.1M, net income −$81.4M, EPS -0.42
Largest institutional holders of BLUE
- Nuveen Asset Management, LLC — $106K
- Sandy Spring Bank — $162
Recent BLUE insider trades
- Mar 3, 2025: Obenshain Andrew sold 921 shares ($3.61K)
- Mar 3, 2025: Klima Thomas J sold 500 shares ($1.96K)
- Mar 3, 2025: Colvin Richard A sold 584 shares ($2.29K)
- Feb 3, 2025: Obenshain Andrew sold 86 shares ($636)
Who owns the most BLUE stock?
The largest institutional holders of bluebird bio, Inc. in the latest 13F filings are Nuveen Asset Management, LLC ($106K), Sandy Spring Bank ($162).
Are insiders buying or selling BLUE?
No open-market insider buys or sells of bluebird bio, Inc. were reported in the last 12 months.
What was BLUE's revenue last quarter?
bluebird bio, Inc. reported revenue of $38.7M for the quarter ended March 31, 2025, with net income of −$29.1M.